Jenny Klintman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6962244/publications.pdf

Version: 2024-02-01

840585 887953 19 636 11 17 citations h-index g-index papers 19 19 19 1060 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature, 2003, 421, 547-551.	13.7	344
2	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood, 2021, 137, 2800-2816.	0.6	51
3	Application of wholeâ€exome sequencing to direct the specific functional testing and diagnosis of rare inherited bleeding disorders in patients from the Ã−resund Region, Scandinavia. British Journal of Haematology, 2017, 179, 308-322.	1.2	49
4	Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-Î ² signaling in vivo. Experimental Hematology, 2005, 33, 592-596.	0.2	40
5	Combination of FVIII and byâ€passing agent potentiates <i>in vitro</i> thrombin production in haemophilia A inhibitor plasma. British Journal of Haematology, 2010, 151, 381-386.	1.2	29
6	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica, 2019, 104, 797-804.	1.7	28
7	Clinicalâ€grade validation of whole genome sequencing reveals robust detection of lowâ€frequency variants and copy number alterations in CLL. British Journal of Haematology, 2018, 182, 412-417.	1.2	19
8	Antibody formation and specificity in <scp>B</scp> ethesdaâ€negative brother pairs with haemophilia <scp>A</scp> . Haemophilia, 2013, 19, 106-112.	1.0	18
9	SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. Cell Reports, 2020, 31, 107640.	2.9	16
10	Longâ€term antiâ€∢scp>FVIII antibody response in <scp>B</scp> ethesdaâ€negative haemophilia <scp>A</scp> patients receiving continuous replacement therapy. British Journal of Haematology, 2013, 163, 385-392.	1.2	14
11	Thrombin generation <i>in vitro</i> in the presence of byâ€passing agents in siblings with severe haemophilia A. Haemophilia, 2010, 16, e210-5.	1.0	12
12	At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature. Therapeutic Apheresis and Dialysis, 2017, 21, 304-319.	0.4	5
13	Clinical characterization and identification of rare genetic variants in atypical hemolytic uremic syndrome: A Swedish retrospective observational study. Therapeutic Apheresis and Dialysis, 2021, 25, 988-1000.	0.4	4
14	Hematopoietic Stem Cells Overexpressing Smad7 Exhibit Increased Self-Renewal and Regeneration Capacity in Vivo Blood, 2004, 104, 561-561.	0.6	2
15	Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Î ⁻ - New Insights from the Hemophilia Inhibitor PUP Study (HIPS). Blood, 2017, 130, 88-88.	0.6	2
16	Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens. Haemophilia, 2022, 28, 239-246.	1.0	2
17	Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007–2012. Nephrology, 2017, 22, 555-561.	0.7	1
18	Epidemiological aspects of inhibitor development in hemophilia and strategies of management. Expert Opinion on Orphan Drugs, 2016, 4, 153-168.	0.5	0

#	Article	IF	CITATIONS
19	Biomarkers of complement and platelet activation are not correlated with the one or twenty-four hours corrected count increments in prophylactically platelet transfused hematological patients: a prospective cohort study. Platelets, 2021, , 1-10.	1.1	O